Effects of early abciximab administration before primary percutaneous coronary intervention on left ventricular function assessed by cardiac magnetic resonance

Kardiologia Polska

Volumn 66, Issue 6, 2008, Pages 617-622

  Rakowski, Tomasz ^a   Mielecki, Waldemar ^a   Brzozowska Czarnek, Agata ^a   Dziewierz, Artur ^a   Siudak, Zbigniew ^a   Legutko, Jacek ^a   Rzeszutko, Łukasz ^a   Urbanik, Andrzej ^a   Dubiel, Jacek S ^a   Dudek, Dariusz ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Abciximab; Magnetic resonance; Myocardial infarction; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; GADOLINIUM; HEPARIN;

ADULT; ANGIOGRAPHY; ARTICLE; CARDIOGENIC SHOCK; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE END SYSTOLIC VOLUME; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART VOLUME; HOSPITAL ADMISSION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; THORAX PAIN;

EID: 53549087572     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Van de Werf F, Ardissino D, Betriu A, et al; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
3. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759-65.
4. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007; 28: 443-9.
5. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002; 90: 533-6.
6. Gyöngyösi M, Domanovits H, Benzer W, et al. ReoPro-BRIDGING Study Group. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 2004; 25: 2125-33.
7. Gabriel HM, Oliveira JA, da Silva PC, et al. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv 2006; 68: 218-24.
8. Arntz HR, Schroder JF, Pels K, et al. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study. Eur Heart J 2003; 24 (abstract suppl.): 268.
9. Rakowski T, Zalewski J, Legutko J, et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J 2007; 153: 360-5.
10. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-71.
11. Godicke J, Flather M, Noc M, et al. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 2005; 150: 1015.
12. Bellandi F, Maioli M, Leoncini M, et al. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 2006; 108: 36-42.
13. Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 2007; 49: 1517-24.
14. Bellenger NG, Davies LC, Francis JM, et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000; 2: 271-8.
15. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI 3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104: 636-41.
16. De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004; 43: 1363-7.
17. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367: 579-88.
18. FINESSE trial results presented by Dr Stephen Ellis on September 3rd 2007 at European Society of Cardiology Congress in Vienna. ttp://webcasts.prous.com/ esc2007/article.asp?CID=YY&CLID=2&AID =349#; return%20false; (assessed November 30th, 2007).
19. Dudek D, Siudak Z, Janzon M, et al. Patients transferred for primary PCI display reduced mortality when treatment with abciximab was started early compared with abciximab given in the cathlab. Results from the EUROTRANSFER Registry. Eur Heart J 2007; 28: 384 (abstract).